The Motley Fool··Jeff SiegelPfizer at Crossroads: Patent Cliffs Offset by Oncology Bet and Dividend Yield
Pfizer faces patent cliff headwinds and COVID revenue decline, but oncology expansion and 6%+ dividend yield keep stock at "hold" with modest upside potential.
PFEdividend yieldAntibody-Drug Conjugates